The nascent electric vehicle (“EV”) industry has presented an opportunity for sectors that weren’t traditionally associated with the automotive industry. Battery makers, for instance, are looking at a lucrative partnership with the EV sector for the foreseeable future, while tech companies such as Sony and Apple are slowly wading into the electric vehicle space as well. As demand for electric vehicles rises and green vehicles take over the roads, those in commercial real estate will be looking at a lucrative business opportunity: EV charging stations.
Unlike conventional vehicles, which run on gas-powered internal combustion engines, electric vehicles are powered by rechargeable lithium-ion batteries. At the moment, the U.S. Department of Energy has registered around 40,000 public charging stations to cater to the 1.6 million EVs on American roads. President Joe Biden has set an ambitious target to roll out 500,000 public EV charging stations by 2030, and as EVs start seeing widespread adoption, the demand for public charging stations will be at an all-time high.
There are around 150,000 gas stations in America, and for years, decades really, more than 80% have had convenience stores on-site to sell to drivers who stop to refuel. However, conventional gas-powered cars take just a few minutes to fuel, meaning drivers have, on average, two to three minutes to shop. Electric vehicles, on the other hand, can take a while to charge, with even the fastest DC chargers taking up to 20 minutes.
This results in an increased amount of time drivers spend on nonfueling-related activities, referred to as dwell time. According to ChargePoint, a company that supplies EV charge ports, EV drivers may have dwell times of up to 50 minutes. Since public EV chargers are relatively harmless compared to gas stations, they can be located nearly anywhere, with shopping malls, hotels and even grocery stores installing EV chargers on their premises.
Even though drivers usually spend just a couple of minutes on site, the overall convenience store sector in America generated $648.8 billion in sales in 2019. With up to 50 minutes in dwell time, how much would public EV chargers with onsite convenience stores bring in? The numbers will definitely be low as EV technology is relatively new and quite expensive, but as these vehicles become more mainstream and affordable, they will undoubtedly pick up.
According to Jacob Schram, a senior advisor at McKinsey, the growing EV industry doesn’t spell doom for gas stations. Even though they will lose plenty of fuel volume, adding EV chargers and products that cater to EV drivers will keep them in the game. And needless to say, those in the commercial real estate segment can make a killing by availing space for constructing charging stations of the future.
Eco-friendly travel is offering lots of other opportunities, and that could explain why Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) has opted not only to invest but also be an active operator within the renewable energy sector through its push to establish thousands of hydrogen fuel cell stations in locations having gas stations.
NOTE TO INVESTORS: The latest news and updates relating to Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) are available in the company’s newsroom at https://ibn.fm/MOTNF
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
ORLANDO, Fla., March 09, 2021 — Last month we introduced our readership to XPhyto Therapeutics Corp. (XPHYF). At such time, we mentioned that the Company is also involved in psychedelics and that we would dive into that matter at a later date.
Today’s that date.
For the uninitiated, psychedelic companies have been enjoying increased interest in North American stock markets as research portends significant possible clinical use. Take a look at this article from Forbes .
Here’s a brief excerpt:
“Like cannabis, the psychedelics industry has been growing at a locomotive pace. A key reason is an intriguing trend within the mental health community: the evolving acceptance of psychedelic drugs for treating depression and other mental disorders.
XPhyto has a world view, having published a couple significant psychedelic benchmark releases in February 2021 alone.
Take a look:
XPhyto Announces Psychedelic Pharmaceutical Production Agreement
XPhyto Laboratories Inc, its wholly owned Alberta subsidiary, has signed an agreement with Applied Pharmaceutical Innovation (“Applied”) for the synthesis of pharmaceutical grade psychedelic compounds and the parallel development of the standard operating procedures necessary to obtain regulatory approval for the respective commercial production process. The industrial-scale production of standardized active pharmaceutical ingredients is an important part of XPhyto’s psychedelic pharmaceutical program as the Company anticipates a shortage of large-scale supply of certain approved and standardized pharmaceutical grade psychedelics.
XPhyto Adds Mescaline Production to Psychedelic Medicine Programs
XPhyto Therapeutics Corp. is pleased to announce that XPhyto Laboratories Inc., its wholly owned Alberta subsidiary, has added mescaline production to its psychedelic medicine programs. Further to the Company’s press release dated February 3, 2021, the capacity under contract with Applied Pharmaceutical Innovation will focus on the synthesis of pharmaceutical grade mescaline. Mescaline has been anecdotally recognized as a relatively safe psychedelic drug and has shown particular promise for the treatment of addiction and depression.
FYI, this is in addition to the Company’s European-based psilocybin biotechnology production development.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe and is currently focused on regulatory approval and commercialization of medical products for European markets.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (“EMC”), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
The best source for full disclosure about the company is the company itself, SEDAR or CSE profile pages for regulatory filings and news releases.
EMC has been paid $150,000 by XPhyto Therapeutics Corp. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php .
Researchers from MIT have developed an amputation surgery that can assist amputees to control their residual muscles better. The researchers say that this should help patients have better control of their prosthetic limbs while also reducing phantom limb pain.
Many muscles that are used to control the movement of an individual’s limbs occur in pairs, which alternately contract and stretch. When a limb is amputated using the conventional method, sensory feedback is cut off, and the movement of these muscles is restricted, which makes it even harder for amputees to sense any force applied to their prosthetic limbs or to feel where those limbs are.
In majority of amputations, muscle pairs that control the joints, such as ankles and elbows, are cleaved. However, the team of researchers has discovered that rejoining these muscle pairs offers amputees much better sensory feedback.
The lead author of the study, MIT postdoc Shriya Srinivasan, stated that their study as well as prior studies had demonstrated that patients would have more control over their residual muscles if they could move them. She explained that if amputees were able to move the muscles that moved their phantom limbs, they would find it easier to use their prostheses.
The paper was published in the “Proceedings of the National Academy of Sciences” journal. The researchers found that the patients who had undergone the antagonist myoneural interface (“AMI”) amputation surgery could control their muscles more accurately than patients who had undergone traditional amputations. These patients also admitted to feeling less pain in the limb that was affected and having more freedom of movement.
Hugh Herr, the study’s senior author, head of the Media Lab’s Bio Mechatronics group and a professor of media arts and sciences explained that the study demonstrated that individuals who had gone the antagonist myoneural interface amputation way could control their prosthetic limbs better, experienced less pain and had a greater range of motion for their phantom joints.
The paper’s other authors include Media Lab research scientist Lisa Freed, visiting scientist Matthew Carty, former Media Lab visiting researcher Zachary Bailey, MIT undergrad Ashley Chia-En Teng, grad student in the Harvard-MIT program in Health Sciences and Technology Hyungeun Song and Media Lab senior research support associates Erica Israel and Samantha Gutierrez-Arango.
Still on the matter of improving the outcomes of patients who undergo different treatment modalities, Predictive Oncology (NASDAQ: POAI) has a massive advantage in the segment of personalized cancer care due to its trove of assets, such as a computerized method of growing cancer tumors in a lab so that personalized treatment alternatives can be generated for a patient.
NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Cancer screenings, treatments declined during COVID-19 pandemic, highlighting need for personalized therapies to improve outcomes
Comprehensive genomic, transcriptomic sequencing of patient samples complete, patient outcome data obtained from UPMC-Magee
Project is template for future partnerships with other healthcare institutions to expand POAI’s AI-driven clinical models to other cancers
The consequences of COVID-19 sent shock waves throughout the healthcare sector in more ways than just the direct impact of coronavirus infections. A recent study (https://ibn.fm/6LLiW) showed that cancer screenings and treatments declined during the pandemic, with the authors cautioning that the fallout could be dramatic. The study’s results certainly highlight the need for more individualized treatment regimens that improve patient outcomes, minimize patient visits and help patients with advanced disease at the time of treatment. This is the area of specialty of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. Through its Helomics division, the Minneapolis-based company has just made a significant stride in its efforts to build AI-driven models of ovarian cancer by completing key data generation milestones in a retrospective study in collaboration with UPMC-Magee Women Hospital, an affiliate of the University of Pittsburgh Schools of the Health Sciences (https://ibn.fm/KSr2G).
While the science and technology are complex, the overarching concept isn’t: Test drugs on individual tumors in a lab setting to better inform doctors’ decisions in the real world. Effectively, Helomics performs chemotherapy on a patient’s tumor before the patient gets the drug to provide the oncologist with information on what may or may not work before the oncologist ultimately prescribes a treatment plan.
During more than 15 years of clinical testing, Helomics has amassed a proprietary knowledge base, coined TumorSpace(TM), of more than 150,000 tumor drug response profiles. Simply, Helomics grows patient tumors and tests how they respond to drugs, constantly analyzing and collating data as it builds multi-omic predictive models of tumor drug response and outcome. “Multi-omic”—biotech speak for integrating data collected from different omic levels (meaning things like genomes, proteome, etc.) to understand interactions and influence on disease pathogenesis—involves using cutting-edge machine learning technology to combine a drug response profile with a genomic profile to deliver a more meaningful and effective impact than genomics alone could.
Helomics currently provides treatment option recommendations to personalize therapy based on tumor profiles as it continues development of its AI-driven models. Once the AI models are complete and validated, it will move exclusively to the AI-driven computer models.
As it happens, looking back is often the best way to move forward. That was the purpose of the study with UPMC-Magee Women Hospital. Comprehensive genomic and transcriptomic sequencing of patient samples is now complete, and patient outcome data has been obtained from UPMC-Magee. These data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.
“The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,” said Predictive Oncology CEO Dr. Carl Schwartz. “Furthermore, this project is a template we can use to partner with other healthcare institutions and expand our AI-driven clinical models to other cancers.”
According to the American Cancer Society, about 21,410 women will receive a new diagnosis of ovarian cancer this year and approximately 13,770 women will die from the disease.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Mohawk Group (NASDAQ: MWK), a technology-enabled consumer products company, reported its financial and business results for the fourth quarter and full year ended Dec. 31, 2020. Highlights of the report include a 61.9% increase in quarterly net revenue, totaling $41.5 million compared to $25.6 million in Q4 2019. Full-year net revenue saw a slightly higher increase, landing at $187.7 million, a 62.3% increase over 2019’s $114.5 million. Other numbers looked good, with full-year and fourth-quarter gross margins improving, fixed operating expenses decreasing, and full-year contribution margin reaching 13.5% over 2.2% in 2019. In business news, the company launched five new products in the last quarter, bringing the total launched products in FY 2020 to 37, compared to 32 the year before. In addition, the company announced a new CFO and appointed heads of corporate development in Europe and North America, with both positions focused on the company’s M&A pipeline. “I am proud of our team for delivering a strong Q4 and for our full-year results,” said Mohawk Group co-founder and CEO Yaniv Sarig in the press release. “Looking ahead in 2021, we expect to continue the momentum following our Healing Solutions acquisition as we continue to accelerate our accretive M&A strategy. We are currently evaluating a strong pipeline of potential M&A targets that in total have trailing twelve month’s net revenue of $522 million and trailing twelve month’s EBITDA of $97 million.”
Mohawk Group is a rapidly growing technology-enabled consumer products company that uses machine learning, natural language processing and data analytics to design, develop, market and sell products. Mohawk predominantly operates through online retail channels such as Amazon and Walmart. Mohawk has twelve owned and operated brands and sells products in multiple categories, including home and kitchen appliances, kitchenware, environmental appliances (i.e., dehumidifiers and air conditioners), beauty-related products and, to a lesser extent, consumer electronics. Mohawk was founded on the premise that if a company selling consumer packaged goods was founded today, it would apply artificial intelligence and machine learning, the synthesis of massive quantities of data and the use of social proof to validate high-caliber product offerings as opposed to over-reliance on brand value and other traditional marketing tactics. For more information about this company, please visit www.MohawkGP.com.
NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at http://ibn.fm/MWK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Ideanomics (NASDAQ: IDEX) today announced that it has acquired 20% of Italian Energica Motor Company S.p.A., a developer of high-performance, 100% battery-powered motorbikes, for the consideration of $13.2 million. With this move, which marks continued investment in European-based OEM, Ideanomics expands its global footprint in the electric vehicle (“EV”) industry. “Energica has combined zero emissions EV technology with high-performance engineering synonymous with Italy’s Motor Valley to create a range of exceptional products for the motorcycle market,” said Alf Poor, CEO of Ideanomics. “It also has proprietary EV battery and DC fast-charging systems that have applications and synergies with Ideanomics Mobility. We are very impressed with Livia and her team, and we look forward to supporting them through their next phases of growth.”
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The company’s Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under its innovative sales to financing to charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and the company’s shareholders with the opportunity to participate in high-potential, growth industries. Ideanomics is headquartered in New York, NY, with offices in Beijing, Hangzhou and Qingdao and operations in the U.S., China, Ukraine, and Malaysia. For more information, visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, announced that according to a recent NielsenIQ report, its OTC topical products were ranked number-one in both sales dollars and units sold at a major Food & Drug Mass (“FDM”) retailer. The FDM channel is the largest sales opportunity for HempFusion’s products as 41% of CBD consumers have recently started shopping in-store again for products that contain CBD, according to a recent study. Those numbers were supported as CBD specialty retailers and pharmacies saw an uptick in consumer-reported purchasing. “Ranking #1 across all measured data, including #1 in sales by dollar volume and #1 by SKU volume, is a tremendous honor,” said HempFusion co-founder and CEO Jason Mitchell in the press release. “Consumers are validating our team’s mission of providing best-in-class products that adhere to the highest standards of regulatory compliance. Since its inception in 2015, HempFusion’s goal has been to develop and provide consumers with the highest quality products on the market, without compromise. We are meticulous in sourcing the right raw materials, ingredients, and delivery methods to help consumers live a more balanced lifestyle, and the FDM channel provides us with an unprecedented distribution opportunity to help us reach those consumers.”
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in store or online. For more information about the company, visit www.HempFusion.com.
NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at http://cnw.fm/CBDHF
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading producer of uranium and critical minerals in the United States, today announced that the first shipments of natural monazite ore arrived this past weekend at the company’s White Mesa Mill in Blanding, Utah. According to the update, the material was separated by The Chemours Company at its Offerman Mineral Sand Plant in Georgia and transported by truck to the White Mesa Mill. In the coming weeks, Energy Fuels expects to gradually ramp-up production of an intermediate rare earth element (“REE”) product, called a “mixed REE carbonate,” which will then advance to REE separation, the next stage in the REE value chain. Energy Fuels also expects to recover the uranium in the ore, which will be used as fuel for the generation of clean, carbon-free nuclear energy. “Over the past few months, Energy Fuels, Neo and Chemours have quietly worked to create something very significant: a new, fully-integrated, U.S.- Europe rare earth supply chain. This weekend’s shipments of monazite ore from Chemours to Energy Fuels marks the beginning of operations for what we believe will become a burgeoning supply chain,” said Mark S. Chalmers, president and CEO of Energy Fuels. “There is a lot of excitement building for rare earths, because they make many clean energy and advanced technologies possible, including electric vehicles, wind generation, batteries and advanced electronics. Today’s announcement is a key milestone as our companies create, refine and grow a sustainable rare earth supply chain capable of supplying growing demand for clean technologies in the U.S. and Europe.”
Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments.
Cybin appears set for rapid growth as research accelerates, public acceptance grows.
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and neurological conditions, has announced that it has upsized the terms of its “bought deal” offering due to strong demand. The deal size, previously announced at CDN$20,025,000, has increased to aggregate gross proceeds of CDN$30,015,000 as the underwriters have agreed to purchase 13,340,000 units of the company at CDN$2.25 per unit. Cybin intends to use the net proceeds to further develop its clinical trials, novel molecule programs and technologies enhancing the patient experience as well as for working capital and general corporate purposes.
The announced upsize comes against the backdrop of a growing demand for psychedelic companies. The burgeoning sector is attracting increasing attention from investors with more companies going public and rapidly increased research sparking greater public acceptance and potential decriminalization (https://ibn.fm/RS6Y1). The stigma around the compound has started to wane as recent studies point towards the potential use of psilocybin, which is found in “magic” mushrooms, for treating patients suffering from mental health diseases such as depression, anxiety and PTSD.
More and more academic institutions, including those with a world-class reputation such as Johns Hopkins and Imperial College London, are establishing specialized programs to further investigate the role psilocybin could play in the mental health space, especially in alleviating symptoms of major depression. In the past, criminalization and the stigma attached to the compound have hindered researchers from exploring the medical benefits of psilocybin and other psychedelics. More recently, however, the push to remove the barriers to research has been gaining momentum.
Cybin is committed to developing novel therapeutics, delivery methods and treatment regimens based on psychedelic compounds such as psilocybin, DMT, MDMA and other analogues to potentially treat neurological disorders. The company is working to become the first company to bring a psilocybin drug to market targeting major depressive disorder addressing a vast potential market with an estimated 17 million people in the United States and 300 million people worldwide experience depression (https://ibn.fm/Tn0bb). As a company developing psychedelic therapeutics for psychiatric and neurological conditions and with a strong executive medical and research team that boasts extensive experience in the field, Cybin appears well-positioned within the thriving sector that is set for rapid growth as research accelerates and public acceptance grows.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, today announced its receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation NeuroCap(TM) device. NeuroCap is an advanced electroencephalogram (“EEG”) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. “We are constantly working on new products for the EEG market. In the new version of NeuroCap, we added velcro strips for better adhesion. We also expanded the size range by adding an XS (extra small) size,” said Irina Nazarova, marketing director at Brain Scientific. “And now this device is designed for broader use — in addition to intensive care units and ERs.”
Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) Is ‘One to Watch’
Nextech AR Solutions Corp. is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events
The company provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales
Nextech AR’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University
The company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase
The Nextech AR management team has extensive experience stemming from time with a collection of Fortune 500 companies
Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales.
The company is currently pursuing four unique verticals with its innovative technology, including:
Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
ARitize(TM) for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
ARitize(TM) 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
ARitize(TM) Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.
Unique Marketing Strategy
Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events.
After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow.
Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University.
Growth Capital
Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce.
As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels.
With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021.
Recent Company Highlights
February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (“VXP”) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
January 25, 2021: The company announced that Strategic Site Selection (“SSS”), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.
Management Team
Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional.
Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (“TOIP”).
Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence.
Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte.
Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry.
For more information, visit the company’s website at www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
New Governance Enhancements to Include the Future Appointment of Two New Independent Directors
TEMPE, Ariz., March 08, 2021 — WRAP Technologies, Inc. (NASDAQ: WRAP) (“WRAP” or the “Company”), a global leader in innovative public safety technologies and services, today announced that Tom Smith has been appointed as the Company’s Chief Executive Officer. Mr. Smith had been serving as WRAP’s interim Chief Executive since October 27, 2020. He joined WRAP in March 2019 as the Company’s President and increased sales by 460% in 2020, selling WRAP’s remote restraint public safety device to 36 countries to date.
WRAP also announced that the Company plans to appoint two new independent directors to the Board within 45 days.
Scot Cohen, WRAP’s co-founder and Executive Chairman, commented: “With nearly 30 years serving law enforcement and public safety, we feel Tom’s experience as an industry veteran and proven leader position him for success in serving as WRAP’s Chief Executive Officer. As the co-founder and former President and Chairman of TASER International, Tom has demonstrated the ability to lead an organization through rapid growth.”
“I am excited to continue leading this company and by the opportunity this exceptional team has in front of them to make lasting changes to public safety,” said CEO Tom Smith. “We are a global company dedicated to improving safety in our communities through de-escalation and the avoidance of excessive use of force. In continuing to work closely with law enforcement agencies and other stakeholders, I am optimistic that WRAP will help create a new era of policing and crisis response.”
Today’s announcements stem from the Board’s discussions and ongoing engagement with WRAP’s stockholders. This includes significant support from Elwood “Woody” G. Norris, who is also the Company’s co-founder and Chief Technology Officer. The Company and Mr. Norris have reached an agreement, which, among other things, sets forth the management change and future appointment of two new independent directors to the Board and includes customary standstill and voting provisions that will be filed on a Form 8-K with the Securities and Exchange Commission.
Mr. Norris added: “I look forward to seeing WRAP move forward to meet its full potential. Tom is an energetic visionary with a unique ability to lead and inspire rigorous growth, as evidenced by the level of talent he’s been able to attract since joining WRAP. Having worked with Tom since his appointment as President in 2019, I have complete confidence in his ability to lead WRAP while maintaining alignment with our core mission of providing solutions that enable safer outcomes for both police and the communities they serve.”
About Wrap Technologies
WRAP Technologies (Nasdaq: WRAP) is a global leader in innovating public safety technologies and services that deliver advanced solutions focused on avoiding escalation. The BolaWrap® Remote Restraint device, WRAP’s first product, is a patented, hand-held device that discharges a Kevlar® tether to temporarily restrain from a safe distance. Through many field uses and growing adoption by agencies across the globe, BolaWrap is proving to be an effective tool to safely detain persons without injury. WRAP Reality, the Company’s virtual reality training system, is an immersive training simulator and comprehensive public safety training platform designed to empower first responders with the necessary knowledge to perform in the field. WRAP’s headquarters are located in Tempe, Arizona. For more information, please visit wrap.com .
Trademark Information
BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.
Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for countries outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
Contacts
For Investors:
Wrap Technologies, Inc.
Paul M. Manley
VP – Investor Relations
(612) 834-1804 pmanley@wrap.com
Monday, March 8th, 2021UncategorizedComments Off on $WRAP Appoints Tom Smith as Chief Executive Officer
Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, announced that it has appointed David Bray, a former general manager and corporate officer for Shell Oil Products US, to the advisory board of PowerTap Hydrogen Fueling Company, an investee company. In his new role, Bray will provide insight and expertise in critical product development and services related to accelerating the development of PowerTap’s proprietary modular 1,250 kg hydrogen production and dispensing unit. Bray has more than three decades of experience in the business and strategy development and fuels and marketing sectors. While at Shell, he served as general manager over several different groups, and his work focused heavily on downstream, customer-facing businesses, as well as the future of energy. In addition to his appointment as board member, Bray and his company, Bray Retail Consulting LLC will join PowerTap for one year in a consulting role. Bray, who believes that hydrogen will play a critical role in meeting the energy needs of the Americas in the future, will assist PowerTap as the company works to bring its IP to the market. “We are thrilled to appoint David Bray to PowerTap’s advisory board,” said PowerTap CEO Raghu Kilambi in the press release. “He has a thorough and complete understanding of this industry and has a proven track record of delivery. We are excited to have him join our Advisory Board and as an exclusive consultant as we look to commercialize our PowerTap onsite hydrogen generation with the Andretti Group across the USA.”
Clean Power is an investment company that specializes in investing in private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, Clean Power’s investment mandate is focused on high-return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and seeking liquidity in its investments. For more information about the company, please visit www.CleanPower.Capital.
NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at http://ibn.fm/MOTNF
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The conference is slated to take place from 9:00 a.m.-5:00 p.m. ET on March 17 – 19, 2021, and will feature roundtable discussions with C-suite executives moderated by Maxim Research analysts, fireside chats with live Q&A, as well as presentations from hundreds of domestic and international issuers. According to the update, 180 Life Sciences’ CEO Dr. James Woody will be available for one-on-one meetings, which investors may request through Maxim Group.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Congress passed the Farm Bill in 2018, effectively legalizing the cultivation and sale of industrial hemp and its extracts after decades of prohibition. With farmers across the country taking part in pilot programs, a market for CBD quickly developed. The hemp extract is said to have a wide variety of health benefits, and preliminary reports coupled with anecdotal evidence have been encouraging.
Shatter and wax are without a doubt the most potent and quickest-acting means of consuming CBD. Shatter is an amber, translucent solid that is brittle to the touch while CBD wax looks just like wax and has a consistency similar to coconut oil. Both of them, collectively referred to as wax, are highly concentrated, with up to 80% CBD content, and they have strong long-lasting effects. Here are five things users should know about CBD wax.
There are four different types of wax, depending on the extraction process used to pull the CBD from the plant matter and the texture of the resultant extract. Shatter looks like brittle amber glass; budder is more creamy in texture, much like butter; crumble has a crumbly, grainy texture similar to feta cheese; and live resin is a malleable, dark-yellow concentrate.
Different production methods result in different types of wax. There are numerous extraction methods lab techs use to pull CBD from the plant matter. The butane hash oil (“BHO”) method, which uses butane as the primary solvent during the extraction process, is the most popular. Carbon dioxide extraction uses pressurized carbon dioxide and produces a much cleaner, solvent-free product compared to BHO. Producers also use air pressure and the freeze-dried method to extract the cannabinoids.
CBD wax and shatter are quite safe. To stay on the safe side, consumers should make sure they purchase products from recognizable brands that offer a certificate of analysis to prove they are pure and contaminant free. Additionally, consumers may want to avoid products made using BHO as the extraction method tends to leave traces of butane solvent in the wax.
CBD wax is fast-acting. If users are surprised by how quickly the effects kicked in when they smoke CBD flower, they would be amazed by how instantaneous the effects of CBD wax are. Most users report near-immediate effects, and thanks to their high potency, the effects are quite strong and tend to last long.
CBD wax is not intoxicating. Although marijuana and industrial hemp belong to the same family, there is one major difference: legal industrial hemp contains barely any THC, the cannabinoid responsible for cannabis’ euphoric effects. Consequently, all hemp derivatives, including CBD wax, does not intoxicate users.
As long as consumers buy a high-quality product from a reputable brand, they shouldn’t have to worry about THC contamination or failing a drug test. However, users should note that waxes and shatters are usually used by highly experienced consumers, so make anyone using CBD should conduct plenty of research and, more importantly, consult a doctor before they consume CBD.
Not everyone needs or is comfortable with taking highly concentrated CBD products, and that is where companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) come in. The company has a line of laboratory-tested CBD salves, creams, lotions and edibles that can meet the needs of most consumers in the country.
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
TAAT(TM) Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) has announced that initial steps to roll out its TAAT(TM) product has begun through its previous agreement with CROSSMARK, a Texas-based consumer packaged goods (“CPG”) sales agency. The rollout began in Ohio with the objective of strengthening TAAT’s existing presence in the state. CROSSMARK reports that more than three-quarters of its Ohio retail accounts that have been approached have indicated an interest in carrying the TAAT product; CROSSMARK will be providing service to more than 7,000 convenience stores in Ohio in Q2 2021. The retail rollout kicked off about the same time TAAT launched its online presence, which offers the company’s flagship products, TAAT Original, Smooth andMentholto adult-aged smokers located in certain areas of the country. “These are exciting times for the company as we enter the final month of Q1 2021,” said TAAT CEO Setti Coscarella in the press release. “Now that our product line has had the opportunity to be tested by smokers aged 21+ across Ohio with consistently positive reception, we can start to roll TAAT out more aggressively with the knowledge that we have a solid product formulation and commercialization playbook. . . . We are excited to see the impact CROSSMARK will have on the overall performance of TAAT as we continue our push to capture additional market share in the USD $814 billion global tobacco industry.”
TAAT Lifestyle and Wellness has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, recently served as the exclusive technology host for B. Riley Securities’ 2021 Vision Day. The prestigious event was held on the Sequire Virtual Events platform, which allowed the Sequire community privileged access to sessions and content. The daylong virtual investor conference featured video presentations and fireside chats discussing top stock picks from B. Riley’s award-winning equity research team. “We were honored to have been selected by B. Riley Securities to host its 2021 Vision Day event following our success with the LD Micro Main Event in December,” said SRAX founder and CEO Christopher Miglino in a recent update. “This event is a perfect example of our growing Virtual Event Platform capabilities. We were pleased to work with the B. Riley team and contribute to another successful event.”
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical Division is renewing the development of a new Generation 3 STREAMWAY(R) System for direct-to-drain fluid waste management. According to the update the new device will see no change to its intended use and will not require a separate 501(k) submission with the Food and Drug Administration. In addition, the new design will include key changes to the product that will be smaller, lighter and easier to install with the goal of improving operator reliability, reducing manufacturing costs, increasing durability and simplifying servicing. “Skyline Medical plans to follow shortly with a Generation 3 Plus machine, which includes an integrated on-board vacuum pump so the facility vacuum supply will not be required or at the least can be augmented if needed,” said Dr. Carl Schwartz, CEO of Predictive Oncology.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Net Element (NASDAQ: NETE) is in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc. Mullen has announced entry into a strategic partnership with NexTech Batteries Inc. as an EV battery supplier and key partner for battery development and technologies. Under the collaboration, Mullen plans to produce more than 100,000 vehicles over five years using NexTech lithium sulfur (“Li-S”) pouch format batteries, which are 60% lighter than today’s EVs, improving vehicle efficiency and reducing overall energy consumption. NexTech’s sulphur is sourced from oil refinement by-products, which are fully recyclable, sustainable, ubiquitously available and inexpensive. In addition, Mullen is committed to reducing greenhouse gas emissions in every aspect of its business, including the use of low carbon footprint materials and emerging technologies, in this case, readily available sulphur. “This technology allows Mullen to potentially be below $90/kWh at a pack level, greatly reducing cost to consumers,” said Frank McMahon, Mullen CTO. “The low carbon footprint, high specific energy density and much lower cost to the consumer will make Mullen extremely competitive in this market segment.”
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). That contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visitwww.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide is 100% effective against root-rot disease. This announcement followed a recent round of laboratory tests, “which were conducted by an independent third-party lab,” an article on MustGrow’s novel accomplishment details. MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, becomes the first to develop an effective treatment for this disease. The “patented mustard-derived biopesticide achieved 100% control over Aphanomyces euteiches zoospores (Aphanomyces) within 24 hours and at economic application rates… Aphanomyces is a soil-borne, root-rot disease that destroys peas, lentils and legume crops, commonly referred to as pulse crops. In infected fields, the disease can result in yield losses ranging from 10% to 100% complete destruction… Currently the only available treatments slow down the spread in an attempt to reduce the severity of the disease; no treatments exist that control the devastating root-rot plague. MustGrow’s plant-based biopesticide aims to change that.”
MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high-value crops such as fruit and vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. For more information, visit the company’s website at www.MustGrow.ca.
NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at http://ibn.fm/MGROF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Mohawk Group Holdings (NASDAQ: MWK) is a leading tech-enabled consumer products platform that utilizes machine learning, natural language processing and data analytics to design, develop, market, and sell products. Mohawk’s proprietary AIMEE(R) platform leverages data and artificial intelligence (“AI”) to automate the design, development and launch of best-selling consumer products. The company owns and operates 12 brands to sell consumer products across multiple categories ranging from kitchenware and home appliances to environmental appliances, beauty offerings and even consumer electronics. A recent article discussing the company reads, “AIMEE(R) (AI Mohawk E-commerce Engine) is Mohawk’s proprietary platform that leverages data and AI to: identify new market opportunities; launch new products; automate marketing variables; and analyze and optimize company-owned and operated consumer product brands.”
Mohawk Group Holdings, together with its subsidiaries (“Mohawk”), is a rapidly growing technology-enabled consumer products company that uses machine learning, natural language processing and data analytics to design, develop, market and sell products. Mohawk predominantly operates through online retail channels such as Amazon and Walmart. Mohawk has 12 owned and operated brands and sells products in multiple categories, including home and kitchen appliances, kitchenware, environmental appliances (i.e., dehumidifiers and air conditioners), beauty-related products and, to a lesser extent, consumer electronics. Mohawk was founded on the premise that if a company selling consumer packaged goods was founded today, it would apply artificial intelligence and machine learning, the synthesis of massive quantities of data and the use of social proof to validate high-caliber product offerings as opposed to over-reliance on brand value and other traditional marketing tactics. For more information, visit the company’s website at www.MohawkGp.com.
NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at http://ibn.fm/MWK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Ideanomics Inc. (NASDAQ: IDEX) Acquires 20% Stake in Italian Listed Electric Motorcycle Maker Energica
Ideanomics, Inc. (NASDAQ: IDEX) recently entered into an investment agreement promising to purchase over 6 million Energica ordinary shares using a subscribed-shares arrangement that priced each subscribed share at Euro 1.78
In total, IDEX would invest approximately 13 million dollars in the Italy-based manufacturer of all-electric high-performance motorcycles
According to IDEX CEO Alf Poor, the investment was driven by Energica’s manufacture of high-performance products that produce zero emissions
In 2020, Energica experienced a 187% increase in revenue compared to 2019, and there is high demand for Energica’s motorcycles in the U.S.
Ideanomics (NASDAQ: IDEX), a global company focused on investing in and promoting innovative solutions in the financial and electric vehicle (“E.V.”) spaces, recently entered into an investment agreement with Energica Motor Company S.p.A. (“Energica”), an Italian listed electric motorcycle company, that will see it acquire at least 20% of Energica, upon completion of the requisite transactions.
According to a March 4 announcement issued by Energica, IDEX promised to purchase 64% of the share capital increase, the equivalent of 6,128,703 Energica ordinary shares, in a subscribed-shares arrangement. Notably, subscribed shares are shares that investors promise to buy as part of an initial public offering or a share capital increase (https://ibn.fm/H10Ca).
Under the agreement, IDEX would pay a subscription price of Euro 1.78 per share, arrived at by calculating the weighted average of the official price of Energica shares over the six months prior to the execution of the transaction, bringing IDEX’s total subscribed share capital to Euro 10,909,091. The transaction would be settled in the few days following the publication of the announcement.
Once completed, the transaction will bring the total number of Ideanomics’ wholly-owned businesses and companies wherein it is a direct investor in the EV space to 7 (https://ibn.fm/eFm9U).
The latest investment, Energica, will be part of Ideanomics’ Mobility division and is the second of its kind for IDEX, which acquired a controlling stake in Treeletrik’s sales and distribution arm in March 2019. At the time, Treeletrik, which manufactures all-electric bikes, was the only licensed EV manufacturer in Malaysia. Therefore, the investment in Energica looks like a calculated strategy in Ideanomics’ quest for a wholesome portfolio that includes every category of E.V.s, namely buses, vans, cars, trucks, and motorcycles, also allowing battery technology synergies to play out between Energica and Treeletik
Energica, the first Italian manufacturer of high-performance electric motorcycles, has posted growth in its revenue and order backlog year-on-year. According to its preliminary 2020 turnover report, the manufacturer posted Euro 6 million in revenue, constituting a 187% increase from the figure reported at a similar period in 2019 (https://ibn.fm/ARZNJ), despite the vagaries brought by the pandemic.
“Energica has combined zero emission E.V. technology with the pedigree of high-performance mobility synonymous with Italy’s Motor Valley to create a range of exceptional products for the high-performance motorcycle market,” Alf Poor, CEO of Ideanomics, said of the company. “We were very impressed with Livia (Energica’s CEO) and her team throughout our discussion, and we are very pleased to support them through their next phase of growth.”
In the first two months of the 2021 fiscal year – starting December 2020 – Energica had already received new orders valued at over Euro 2.9 million and equivalent to 49.7% of the orders it received throughout 2020. 30% of these orders were from the United States. Moreover, the U.S. orders received between March 25 and April 28 accounted for 41% of the total. These figures signal that Ideanomics’ investment in the motorcycle manufacturer could also be due to the increasing popularity of Energica’s motorcycles in the North American market.
On her part, Livia Cevolini voiced her pride in being part of a unified platform that shared the same vision. “The creation of a network of innovative companies can only accelerate the growth and adoption of new technologies such as sustainable mobility that sees us among the leaders,” she continued. “The investment will give further strength to the Energica growth already underway in recent years thanks to the innovation brought to our products with the racing experience in MotoE.”
The investment brings Ideanomics closer to realizing its vision to build advanced technology ecosystems that deliver more efficient and environmentally-friendly solutions to the world.
For more information, visit the company’s website at www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Earlier this year, the Capital Markets Modernization Taskforce in the Ontario government gave a few recommendations for improving Ontario’s investment environment. In part, the body advocated for compulsory climate change-related disclosure and recognized that Environmental, Social and Governance standards played a huge role in the market and could impact a company’s financial performance. However, the body proposed a reporting standard that did not account for the social effects and risks of investing and failed to address Indigenous concerns and human rights.
Research conducted by JCAP found that disclosure mattered to investors. The organization discovered that failures to consult Indigenous communities and violations of human rights affected a company’s share prices. The group also found that once any complaints by the body were made public, a decline of share prices, which ranged from 11% to 22%, followed. JCAP also found that investors considered any conflict with local communities a risk to their investment and preferred those conflicts to be disclosed.
An example of this happening in the real world would be Tahoe Resources’ failure to disclose key information about social conflicts. After news about the company’s failure to disclose the opposition it faced from Indigenous communities was publicized, a few class-action lawsuits were launched against the company, paid for by funds that had invested in the mining company divesting from the mining company on account of the human rights concerns.
While the six complaints filed by the JCAP are only part of a small sample, the impact of social conflicts on a company’s share prices can be established by a larger study that focused on the assassinations of 354 civil society activists who were linked to mining projects over the past two decades.
The study found that investors reacted negatively to any assassination event, adding that the market capitalization suffered a cumulative median loss of over $100 million in the 10 days after an assassination.
A lot of research conducted suggests that investors do care about consultation with Indigenous communities and how human rights are affected. Investors consider these factors important to the value of their investments, and for investors to make informed decisions on their investments, they need full disclosure of information.
It is therefore imperative that mining firms pay extreme attention to these issues if their projects are to enjoy sustained investor interest.
In addition to respecting human rights, investors are attracted to mining companies with steady growth in their production and revenues. One such company is Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2). The company has projects in Idaho, Mexico and Germany. All indicators point to the possibility of high yields and production potential over a long term.
NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at https://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
USF and Psilera join other universities across the United States that are also conducting psychedelic research on various psychedelic compounds. Psilera’s objective is to be the pioneer psychedelics company to develop patient-friendly and noninvasive DMT delivery methods.
The company’s CSO and co-founder, Dr. Jackie on Salm, explained that the company was focused on developing new delivery methods that increased treatment accessible to patients.
In order to get the DEA’s nod to study any drugs found in Schedule 1 of the CSA, researchers are required to avail information on the institution from which the studies will be conducted, the research protocol that will be used and their personal qualifications.
Von Salm, along with Psilera’s other co-founder Dr. Chris Witowski, received her doctoral qualifications from the University of South Florida. Von Salm and Witowski both studied the chemistry of natural products. The two based their biotech company startup in the University of South Florida Research Park, where they specialize in the development of medicinal psychedelic compounds.
Psilera Bioscience was established in 2019, and since then, the company, which is one of the members of the USF Connect incubation program, has chemically synthesized various compounds. The company’s DMT delivery device will be evaluated in future study partnerships while the Neuroscience Institute at USF will assess these psychedelic compounds’ effectiveness and safety.
Witowski, who also serves as CEO, stated that the company was happy to deepen its relationship with USF, adding that this milestone would improve how the scientific community understands psychedelics while also aiding in the development of next-gen treatment alternatives for this class of drugs. Additionally, he noted that the approval obtained from the DEA would allow Psilera to significantly speed up its drug formulations and neuromodulator pipeline into the phase of clinical development.
Earlier in 2016, the University of South Florida was elected as Florida’s first emerging preeminent state research university. The institution is in the highest ranked 10 institutions that are awarded patents each year and is among the highest in the country for academic research funding.
The USF incubator program hosts several biotech firms, and with the ongoing construction of additional facilities in the university’s research park, the number will only grow.
More than 700 million people around the world suffer from some form of mental health issue, and it is this massive population of patients that companies such as Cybin Inc. (NEO: CYBN) (OTC: CLXPF) would like to serve using various drugs under development, such as a sublingual film intended to be an alternative to swallowing pills for people with mental health illnesses.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its shares have commenced trading on the OTCQB(R) Venture Market under the symbol “CLXPF.” “With the commencement of trading on the OTCQB, Cybin has achieved another important milestone on its path to advancing mental health care through evidenced-based therapeutics. This additional capital markets exposure offers us greater visibility within the investment community, which should enhance our liquidity and increase our access to institutional and retail investors,” said Doug Drysdale, CEO of Cybin. “This support is extremely valuable to us as we continue to progress our psychedelic drug development programs that target mental health disorders, such as major depressive disorder, and other therapy-resistant psychiatric disorders.”
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Researchers are working on advances in the fields of nanotechnology and biomaterials which may help develop objects that eliminate viruses automatically.
Breakthroughs in the advancements made in both fields could help fight against deadly viruses like the SARS-CoV-2 virus, which is the strain that causes Covid-19.
Scientists from the Indian Institute of Science described various factors being explored by researchers in the field to design surfaces that could fight and eliminate viruses and increase vaccine efficacy.
In their study, which was published in the APL Bioengineering journal, Kaushik Chatterjee, who is one of the authors of the study, explained that they were curious to see how biomaterials could be useful with regard to viral infections.
Biomaterials are usually engineered to mesh with other biological systems in different ways. Biomaterials may include drug delivery systems, surgical mesh, dental implants and joint replacements.
On the other hand, nanotechnology is focused on building small devices and structures at the microscopic level. It has been utilized in the medical field to target certain tissues and cells.
Researchers found that combining the two fields could help vaccines become more effective against viruses. This is not to mean that current vaccines aren’t effective, just that biomaterials-based nanoparticles would make them even more effective.
Sushma Kumari, another author of the study, stated that using biomaterials-based nanoparticles could help stimulate the immune cells which give rise to antibodies during vaccination. She explained that the particles would help make the cells more responsive to protein, which would prompt them to secrete more antibodies.
Concurrently, researchers are also looking into the various ways in which technology can be used to limit the spread of viruses. Presently, the methods used to disinfect surfaces in public areas, from ultraviolet light to aerosols to normal cleaning, require a lot of effort and time.
Bioengineering technologies could help develop antiviral surfaces which could disinfect themselves, thus eliminating the time it takes an individual to clean a surface. Chatterjee noted that viruses usually ended up on surfaces as droplets, which is how a virus spreads when the next person touches the surface with virus droplets on it and picks up the disease.
The study’s authors maintain that while this research is still in its early stages, putting a natural charge on a surface or designing one at the nanotech-level would enable the creation of other items like hospital beds, PPE suits and masks which could naturally eliminate a virus.
Still on the subject of R&D to address the current threats to human health, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) has opted to focus on finding remedies to the cancers which affect the neurological system, especially the brain. Therapies in this segment are projected to be worth $3.4 billion annually by 2025, presenting massive opportunities for growth by CNS Pharmaceuticals.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its CEO and Chairman, James Sapirstein, will participate in a panel discussion during the ROTH Conference slated to be held virtually from March 15-17, 2021. According to the update, the panel, “Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade Away: A discussion of various developmental therapeutics for SARS-CoV-2 infection,” is scheduled to begin at 12:00 p.m. ET on March 15, 2021. During the panel, Sapirstein will discuss the need for drug therapies to address issues related to COVID-19, including the prevalence of gastrointestinal symptoms in an increasing number of people infected by the virus.
In addition, AzurRx BioPharma announced its entry into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 7,858,548 shares of common stock (or common stock equivalent) and warrants to purchase up to an aggregate of 3,929,274 shares of common stock at an effective purchase price of $1.2725 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants are exercisable immediately, at an exercise price of $1.21 per share, and will expire five years following the date of issuance. Subject to the satisfaction of customary conditions, the closing of the offering is expected to occur on or about March 10, 2021. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
AzurRx BioPharma is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs in 2021 using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 immune checkpoint inhibitor colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Monday, March 8th, 2021UncategorizedComments Off on $AZRX Announces Plans to Participate in 33rd Annual ROTH Conference, $10M Registered Direct Offering
Trxade Group (NASDAQ: MEDS), a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience, will be participating in three investor conferences scheduled in March 2021. In all three conferences, Trxade Group CEO Suren Ajjarapu will present valuable information and insights about the company for conference participants. In addition, he is scheduled to participate in one-on-one meetings during each event. Conferences in which Ajjarapu is scheduled to participate include the two-day H.C. Wainwright Global Life Sciences Conference, slated for March 9-10, 2021; the three-day Roth Growth Stock Conference, scheduled for March 15–17, 2021; and the two-day Maxim Group Emerging Growth Conference, which will be held March 17–18, 2021. All three conferences are virtual, online events.
Trxade Group is a health-services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug-procurement marketplace serving a total of 11,800-plus members nationwide and fostering price transparency as well as the Bonum Health brand, offering patient centric telehealth services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics (“DTx”) market, has been selected to participate in the virtual Stephens 2021 Best Ideas Conference. The conference is slated for March 11, 2021. As part of that participation, Dario CEO Erez Raphael and president/general manager Rick Anderson will presenting. Their presentation is scheduled to begin at 9 a.m. ET on March 11; a replay of their presentation will be available following the conference. DarioHealth is committed to change how people with chronic conditions manage their health. The company has one of the highest-rated diabetes and hypertension solutions on the market and is focused on providing next-generation, AI-powered, digital therapeutic solutions in the health-care space.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Residents of the state of Missouri living with terminal, life-threatening or debilitating ailments may soon be able to legally access various psychedelic drugs under a new bill, whose objective is to broaden Missouri’s current Right to Try statute.
A legislation introduced last month by Kansas City Republican Rep. Michael Davis would permit individuals who are seriously ill to use psychedelic substances such as ibogaine, MDMA, mescaline, psilocybin mushrooms, DMT and LSD, when all other approved treatment options have been exhausted and their doctor recommended it.
Davis’ HB 1176 measure calls for the Right to Try law be expanded to include the above psychedelics, which are currently classified as Schedule 1 drugs. The bill also advocates for the statewide reclassification of low-level offenses to be misdemeanors as well as the removal of felony penalties for simple possession of these psychedelic drugs.
Under the state’s current statutes, an individual found in the possession of the psychedelic drugs listed will have their charges classified under a class D felony, with the punishment being a jail term of up to seven years in prison. The Right to Try statute, which was ratified in the state of Missouri in 2014, permits people with terminal ailments to acquire investigational devices and drugs that are yet to receive approval from the FDA but doesn’t allow them to access or use Schedule 1 drugs.
Crossing Paths PAC, a political action and drug policy reform committee released a statement that quotes Davis saying that various psychedelic drugs have years of clinical research that support their safety and effectiveness profiles, yet the Food and Drug Administration has not made any move towards rescheduling these drugs. Davis added that his proposal not only aligned the state’s legislation with federal legislations with regard to investigational drug access but also protected the liberty interests of the states’ residents who believe that these psychedelic drugs could be useful in helping to treat various conditions.
Crossing Paths also observed that in 2018 State Rep. Jim Neely had introduced a bill that would have broadened the Right to Try statute to incorporate medical marijuana access without license caps. While the legislation was approved by the House, it was rejected on the Senate floor.
In addition to this, the HB 1176 legislation would also decrease criminal penalties for individuals who are not patients and are found to be in possession of the drugs listed in the measure. At the moment though, the initiative is yet to be moved to a committee and has no co-sponsors.
In related news, XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is gearing up to be a key player in the psychedelics medicines sector through an agreement intended to conduct research and development on a variety of psychedelic compounds (mescaline and LSD, for example).
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
